Catalyst Wire Dossier Catalyst Wire Dossier

MRT5413 Quadrivalent influenza mRNA vaccine

MRT5413 · Sanofi Pasteur
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MRT5413 Quadrivalent influenza mRNA vaccine, covering 2025-03-19 to 2025-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older [Phase 1, Phase 2]

See pricing